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Notwithstanding the universal recognition of a potential link between stress, and by implication an activated HPA axis, and an inhibition of HPG, data confirming this association in the human are scant and at best indirect. The most revealing data derive from a careful comparison of circadian cortisol secretion in patients with the functional chronic anovulation syndrome to that in eumenorrheic women or in women with other causes of anovulation. Only women with the functional chronic anovulation syndrome were found to be characterized by increased cortisol secretion, usually in the form of an amplified, but phase-intact, circadian excursion (8, 10) . Studies in these women also reveal a blunted cortisol response to exogenous administration of CRH, suggesting that the increase in cortisol secretion may well reflect increased endogenous CRH activity (4, 11) . Increased cortisol secretion has also been noticed in eating disorders or after exercise in many women. Furthermore, elevated levels of CRH in cerebrospinal fluid have been reported in amenorrheic women with anorexia nervosa (12) , although the precise source of this neurohormone in lumbar CSF remains to be clarified. The preceding data suggest that in at least some amenorrheic patients, the endocrine HPA axis has been activated. Yet, there is presently no direct confirmation of a causal relationship between this phenomenon, and the suppression of the GnRH pulse generator and the HPG axis and the induction of the clinical syndrome. Furthermore, the independent association of stress, exercise, or eating disorder with the syndrome has up until now been impossible to confirm. However, it has been reported that although many of the graver stress situations where high rates of secondary amenorrhea occur are associated with malnutrition, in general the amenorrhea antedates the malnutrition (3).
Demonstrating an independent causal association between stress and the HPG axis is a difficult task ahead. In the established syndrome, it may be impossible to trace back toThe concept that physical and emotional stress activates central and peripheral responses that will preserve homeostasis has been well studied in animals. Classically, the main actors in this general adaptational response are believed to be the HPA endocrine axis and the autonomic nervous system (13) . Activation of HPA involves the release of the neurohormone CRH. Although CRH neurons are scattered throughout several brain regions, one of the main area in the response to stress is thought to be located in the parvicellular aspects of the hypothalamic paraventricular nucleus (14) . Central CRH release results both in the activation of the peripheral components of the HPA axis, leading to an increase in ACTH and cortisol, and in the activation of the sympathetic nervous system with increases in glucose release, heart rate, and blood pressure. Activation by stress of the locus ceruleus/autonomic system in the brain stem results in the stimulation of norepinephrine release from several central networks and enhanced arousal and anxiety. CRH may not be the only HPA neurohormone involved in the stress response; there is good evidence in the human and in animals that vasopressin of paraventricular origin is colocalized with CRH in perikarya and secretory granules and coreleased in stress (15, 16) . Vasopressin is known to act synergistically with CRH as an ACTH secretagogue (17) .
The mechanisms that control the activity of the GnRH pulse generator are still chiefly under study, and only recently has evidence of a link and cross-talk between the neuroendocrine HPA axis and the GnRH pulse generator been obtained in the rodent and the nonhuman primate. The first line of evidence derives from the observation that the administration of CRH results in an immediate decrease in pulsatile GnRH and LH release (18, 19) . Similar acute inhibitory effects on gonadotropin secretion after central administration of vasopressin, the second HPA neurohormone, have also been observed in the ovariectomized monkey (20) . Although CRH administration obviously also activates the peripheral endocrine HPA axis resulting in ACTH and cortisol release, the acute inhibition of pulsatile GnRH activity by CRH in the ovariectomized monkey is clearly the result of a central action of CRH. Indeed, inhibition of gonadotropin release cannot be reproduced by a short term ACTH infusion and is still readily observed after CRH administration to the adrenalectomized monkey (21, 22) . Unfortunately, efforts to demonstrate an inhibitory action of CRH on gonadotropin release in the human have not been successful (23, 24) , except by one group of investigators (25, 26) . The controversy perhaps reflects the facts that cerebroventricular injection of the neurohormone is not possible in the human and that at acceptable levels for treatment insufficient amounts of the compound may reach the proper central area after peripheral administration. This topic may have to be reassessed, however, taking into consideration the possibility that the gonadotropin response to CRH may vary according to the ovarian endocrine status.
The relevance of CRH or vasopressin injection data in animals is difficult to interpret, because it is not possible presently to assess whether injected amounts of these compounds are physiological or pharmacological. A more direct line of evidence for an HPA-HPG link would require a demonstration that the neutralization of endogenous HPA neurohormone activity results in the disruption of the hypothesized HPA-HPG link. Such evidence has been obtained in the rat, in which the inhibitory effects of a stressful physical stimulus, such as that resulting from electrical foot shocks, on GnRH and gonadotropin secretion is prevented by cotreatment with a CRH antagonist or antibody (27) .
As mentioned above, the difficulty in studies in the primate is to identify a stress challenge (a stimulus that activates the HPA axis) that is relevant, quantifiable, and reproducible (i.e. in which individuality of the response is minimized), so that comparative experimental protocols can be developed. In initial studies in the nonhuman primate, our group has investigated the effects of an infectious-like stress challenge, such as that which follows the administration of the inflammatory cytokine interleukin-1 (IL-1) or of endotoxin, which is known to release endogenous cytokines (28) . In the monkey, this challenge reliably produces an acute infectious-like syndrome and an activation of HPA, as judged by the increases in central CRH, ACTH, and cortisol release; it also results in the immediate suppression of pulsatile LH and FSH release (29, 30) . A similar effect of endotoxin has been shown in the sheep (31) . Significantly, in the monkey, but not in the rat, the inhibitory effect of IL-1 on LH is prevented by the central injection of a CRH antagonist (30, 32) . In accord with the postulated role of paraventricular vasopressin, an antagonist to this neurohormone is equally effective in this regard (33) . Thus, these data in the primate provide direct support to the concept that one of the mechanisms by which stress is inhibitory to the GnRH pulse generator is through the activation and the central release of neuroendocrine components of the HPA axis. Whether this conclusion is generally applicable or is limited to this particular stress challenge remains to be elucidated.
A word of caution is in order here. There are several instances in the nonhuman primate indicating that an apparent activation of HPA, as determined by an increase in cortisol, does not necessarily translate into a suppression of gonadotropin secretion. For example, experimental data indicate that the increased central CRH activity that follows the reduced cortisol negative feedback induced by metyrapone does not result in an acute inhibition of LH secretion (34) . Other data show that although there is frequently a correlation between activation of HPA and suppression of reproductive hormone secretion in instances of social stress, this link is not present in all individual animals (35) . In a series of studies, no evidence could be provided that fasting-induced LH suppression in the male monkey is the result of the mild HPA activation observed in this instance (36) . Clearly, further research is warranted in both the human and relevant animal species to fully elucidate what central or peripheral mechanisms are required to activate the postulated HPA-HPG link. It is also important to note here that, as expanded upon later in this review, the acute activation of HPA may, under certain circumstances, elicit an increase rather than a decrease in LH release, a result that, because unexpected, may have escaped notice in previous protocols. Unfortunately, a direct demonstration of the role of central CRH on LH secretion has not been possible to date in the human because CRH antagonists are rapidly degraded when given parentally and probably require central administration for effectiveness. However, experiments using µ-opiate receptor antagonists indicate that an increased endogenous opioid activity may somehow also account for the decreased pulsatility of the GnRH pulse generator in patients with functional hypothalamic chronic anovulation. Indeed, studies have shown that the administration of naloxone or naltrexone acutely restores normal LH pulse frequency, at least in a subgroup of these patients (37) . The hypothalamic ß-endorphin center, in fact, resides within the arcuate nucleus of the hypothalamus, which is also the location for the GnRH pulse generator in the primate. In animals, the acute inhibitory action of CRH on pulsatile LH release is also clearly prevented by naloxone or by an antiserum to ß-endorphin (38, 39, 40) . [Interestingly, in the monkey, MSH, a derivative of the same prohormone giving rise to ß-endorphin, can also antagonize the inhibitory effects of CRH or of IL-1 on pulsatile LH secretion (41) . This suggests that the posttranslational processing of POMC may represent a step in the processes that control the response to stress.] As the animal studies suggest that increased endogenous opioid activity reflects, among many possible other causes, enhanced central CRH release and mediates the endocrine actions of CRH on the HPG axis, the above observation in the human may be viewed in support, if only indirectly, of the existence of a HPA-HPG link. After relevant and standardized stress paradigms are devised and tested for their effect on HPG, one potential complication is that the varying ovarian endocrine status throughout the menstrual cycle may modulate the response differentially. Thus, stress challenges should be tested at various stages of the cycle, and the responses compared.
In this endeavor, investigators may have to be careful not to generalize data, because each particular stress challenge may well activate HPA through a different central pathway with its own particular sensitivity to the ovarian steroids. Experiments in the nonhuman primate serve to illustrate this aspect. As an example, although small amounts of estradiol appear to enhance the inhibitory effect of an immobilization or of a hypoglycemic stress on gonadotropin secretion (42, 43) , they exert a protective action against the effect of an inflammatory-like stress challenge (44) .
In the rodent, there is some evidence that sex steroids may interact with both central and peripheral substrates of stress, thereby possibly modifying the HPA response. Such effects may reflect the presence of estrogen-responsive elements in the CRH gene promoter area and modulatory actions of estrogen on CRH gene expression (45) . Thus, it may be that reported observations of slight gender differences in cortisol levels or of a sexual dimorphism in the immune/inflammatory reaction or in autoimmune disease may reflect direct stimulatory effects of estrogen on the CRH gene (46, 47) . The latter may also explain the greater activity of CRH at proestrous in the rat (48) or the enhancement of cortisol release in estrogen-treated ovariectomized monkeys (49) . Yet, it is important to emphasize at this stage that not all studies demonstrate a positive correlation between estrogen and HPA activity (50) and in some instances a reverse relationship has been noted (51, 52) . The overwhelming conclusion from a review of the literature on this subject is the remaining need for systematic comparative studies of the acute effects of well defined stress challenges on the HPG axis at various stages of the menstrual cycle. In this circumstance, it is thus impossible to draw general conclusions for this article. Although the classical HPA-HPG link implies that activation of HPA will cause a decline in gonadotropin secretion, recent studies in our laboratory suggest that a reverse outcome is possible under a defined endocrine condition. Indeed, activation of HPA by IL-1 or endotoxin in the monkey during the midlate follicular phase (but not the early follicular phase or the luteal phase) results in an acute release of LH (52) . This observation evidently contrasts with the above-reported inhibitory effect of the cytokine on pulsatile LH secretion in the absence of estradiol (30), a result more in tune with the classical theory. A release of LH after HPA activation can also be produced in the ovariectomized monkey replaced with mid-to late follicular phase estradiol levels (53) .
That such a surprising result is not confined to the nonhuman primate is suggested by observations in postmenopausal women receiving estrogen replacement in whom a similar increase in LH was noted in response to endotoxin administration (Wardlaw, S., personal communication). Differences between species may occur because in the rodent IL-1 exerts an inhibitory effect on gonadotropin release at all stages of the estrous cycle (54) . In the ewe, however, an increase in LH was also observed after central CRH administration, but again only in steroid-replaced animals (55) . In the monkey, our studies indicate that the factor that is probably responsible for this acute stimulatory effect of HPA on LH release may be progesterone, as this effect is readily prevented by the administration of a progesterone antagonist (53) . We have speculated that in stress the small but significant increase in adrenal progesterone that occurs in response to HPA activation, synergizes with circulating estradiol to enhance LH secretion. In support of this hypothesis is the observation that the increase in LH is prevented by the administration of a CRH antagonist, demonstrating that HPA activation is required for this effect to occur (53) . That such an increase in LH is not observed when the cytokine is given earlier in the follicular phase probably reflects the fact that at lower concentrations, estradiol cannot synergize with progesterone. Lest the reader conclude that an increase in LH after activation of HPA is an exclusive characteristic of one type of stress, it should be noted that this phenomenon was also reported in response to a single bout of exercise in untrained women during the midfollicular phase (but not the luteal phase) and in eumenorrheic runners immediately after a race (56, 57) .
Are these unexpected observations of a stimulatory effect of the HPA-HPG link just a curiosity or could these be of any relevance to the reproductive cycle? It is obviously too premature to tell, but one could speculate that this response may highlight a cycle stageor endocrine-specific recognition of an acute stress reaction and perhaps represent a mechanism by which an acute stress stimulus, insufficient to interrupt the reproductive cycle, may nonetheless subtly interfere with normal cyclic function. Although there are no data in the literature specifically related to the effects of a stress-induced premature increase in LH in the mid-to late follicular phase, there are several reports indicating that elevated LH concentrations at that stage of the cycle may damage the maturing follicle and/or the oocyte, desynchronize the ovulatory signal from a timely follicular maturation process, and/or interfere with fecundity (58, 59, 60, 61) . Although the long term consequences of chronic stress presumably include amenorrhea, the initial effects of an activation of HPA on cyclic events have not been studied. Our initial studies in the monkey have dealt with the effects of a moderate 5-day infectiouslike stress during the midfollicular phase of the cycle, a stress that produces mild flu-like symptoms. The results, if confirmed by other studies, are of potential interest, first because they show that a short term stress may exert effects on the cycle well past its duration, and second because it could be argued that this stress challenge, although inducing endocrine effects too subtle to be readily detected in a clinical environment and insufficient to interrupt the menstrual cycle, may, in fact, be substantial enough to potentially interfere with fertility. Two cyclic disturbances occur in response to this short-lived stress challenge (62) . First, HPA activation at this stage of the cycle results in a prolongation of the follicular phase that in a subgroup of monkeys exceeds well over 1 week. Second, the stress challenge also invariably results in a reduced luteal function in the form of diminished progesterone secretion during the luteal phase in the subsequent cycle. These cyclic abnormalities may be representative of a more universal initial response to HPA activation and as such be part of the symptomatology accompanying the initial events in this syndrome. Irregular bleeding patterns, long irregular cycles, and abnormal luteal phases should indeed be considered part of the spectrum of symptoms in the functional chronic anovulation syndrome (2) . Although our own preliminary data in the monkey are presently limited to a single type of stress, there have been observations of a higher incidence of luteal deficiency in women after the initiation of an exercise program (63, 64) . Although we have focused this review on neuroendocrine and endocrine HPA-HPG interactions, autocrine and paracrine regulatory responses may also have to be considered in future studies. Recent observations have shown that CRH is present in several peripheral tissues. In the ovary, immunoreactive CRH and CRH receptors are identified in thecal cells, stroma, and mature oocytes (65) . In some studies, CRH has been shown to inhibit steroid biosynthesis by human granulosa-lutein cells in culture through mechanisms that involve the CRH and IL-1 receptors (66, 67) . Human and rat uteri have been shown to express the CRH gene, and it has been speculated that endometrial CRH may also participate in physiological events in that organ (68, 69) . The treatment of patients with functional hypothalamic chronic anovulation is multifactorial and beyond the scope of this review. It may include taking care of the behavioral variables, of the hypoestrogenism relative to the quiescent HPG axis, and of infertility. With regard to the latter, pulsatile GnRH or gonadotropin therapies are usually successful (2) . Although, as mentioned above, the injection of an opiate antagonist may acutely reactivate pulsatile gonadotropin secretion (37), conflicting results have been obtained in regard to a long term benefit of this treatment. Two studies have reported successful rates in inducing ovulatory cycles with naltrexone, but another failed to demonstrate any benefit over placebo treatment in women with hypothalamic amenorrhea (70, 71, 72) .
On the road to acyclicity and infertility
Potential local effects of stress
Hope for a different therapeutic tool may be found in a new class of nonpeptide CRH antagonists that have been shown to exert a potent and selective antagonism to CRH (73, 74, 75) . These new antagonists may prove to be more useful therapeutically than those presently available, because of their ability to be administered parentally. An example of a specific condition in which a CRH antagonist may be potentially effective would be to prevent the premature increase in LH in the mid-to late follicular phase that occurs in a sizable number of unstimulated cycles (60) , if indeed this increase were to reflect an acute stress response. In this condition, the CRH antagonist may prevent the small rise in adrenal progesterone that is probably responsible for the LH increase (see above) and allow for the normal continuation of folliculogenesis. A CRH antagonist therapy may also be attempted in patients with the established functional hypothalamic amenorrhea syndrome to restore GnRH pulsatility, estrogen secretion, and a normal menstrual cycle. Whether therapy with this single antagonist would be successful in reversing a well established chronic condition is difficult to predict. Neuroendocrine aspects in chronic stress have not yet been investigated in the primate, and accounts in the rodent suggest that alternative HPA secretagogues may become prominent in the chronic stress condition. For example, in the rat it is thought that vasopressin plays a more specific role in chronic stress by sustaining HPA responsiveness at a time when, at least in some stress paradigms, the CRH response rapidly desensitizes. For instance, in cases of repeated restraint stress the proportion of vasopressin-containing CRH neurons increases significantly, and data suggest that there may be emergence of an isolated vasopressin response (76) . Vasopressin is very effective in influencing LH secretion in the primate, as detailed above, but the relative roles of both neurohormones during chronic stress remains unknown. It may then well be that a successful treatment may require the addition of antivasopressin therapy as well. Although there is general agreement that the functional hypothalamic amenorrhea syndrome is linked to psychogenic stress and the resultant suppression of the normal activity of the GnRH pulse generator, the independent association between stress and the inhibition of the GnRH pulse generator remains to be demonstrated in the human. The challenge for the researcher remains to identify relevant and reliable stress paradigms so that prospective investigations of an HPA-HPG link can be initiated. Stress affects multiple sites; behavioral, metabolic, cardiac, and endocrine responses can be activated (Fig. 1 ) . Stress research will be complicated by the probability that different stress challenges may activate each site to varying degrees and that each site may be variously sensitized by the presence of each ovarian steroid. In regard to the neuroendocrine response to stress, we can predict from animal studies that both HPA neuropeptides, CRH and vasopressin, and the endogenous opioid peptides will play a role in the inhibition by stress of the hypothalamic-pituitary-ovarian axis. Both the ability of CRH and vasopressin to inhibit GnRH and gonadotropin secretion and their mediation of the effects of several types of stress challenges have been demonstrated. Initial studies in the nonhuman primate of the effects of a short term stress episode on the menstrual cycle are of potential interest to the clinician because they indicate that although a stress may be insufficient to produce amenorrhea, it may interfere with the normal cycle in subtle ways and thereby potentially affect normal fertility. Primate studies have also described a paradoxical gonadotropin response to a stress challenge in the presence of estradiol, such as during the mid-to late follicular phase, resulting in an acute release of LH. The factor most likely responsible for this stimulatory effect of HPA on LH release, at least in the acute situation, may be progesterone released by the adrenals in response to HPA activation (Fig. 2 ) . Whether this represents an additional mechanism by which an acute stress stimulus, again insufficient to interrupt the reproductive cycle, may interfere with the normal progression of folliculogenesis and with fertility remains to be determined.
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